NCT06569095Recruiting
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry in Patients Receiving Allotransplantation: a Multi-center, Prospective Clinical Study
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
Presently, multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) have been used for disease load, including measurable residual disease (MRD), monitoring in patients with myelodysplastic syndrome (MDS). MFC is the most commonly method for disease load evaluation. In patients with acute myeloid leukemia, leukemia stem cells (LSCs) determined using MFC for leukemia load and MRD detection is superior to traditional MFC method. In the investigators previous single center study, the investigators demonstrated that detection of disease load, including MRD, by MFC in patients with MDS-EB is superior to predict outcomes after allogeneic stem cell transplantation. Here, the investigators will perform a multi-center, prospective clinical trial to investigate the predictive values of MDS-SC in patients with MDS-EB who received allografting.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 163 (estimated)
- First submitted
- 15 Jul 2024
- Start date
- 9 Dec 2024
- Primary completion date
- 17 Dec 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT06569095
What you commit to
- Study type: Observational
- Planned participants: 163
- From 9 Dec 2024 to the primary completion date, 17 Dec 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled serious infection;
- Other conditions that do not tolerate transplantation or other therapies.
Lab values
- Patient has severe cardiac (ejection fraction \<50%), hepatic (total bilirubin \>34μmol/L, ALT, AST \>2x upper limit of normal) or renal (blood creatinine \>130μmol/L) disease；
Other
- Subjects who cannot comply with the study;
Who the study is looking for
- Patients with Myelodysplastic syndromes;
- Between 15 and 70 years old;
- Subjects are able to provide written informed consent.
Age in the registry: 15 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Wuhan Tongji Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.